Analysts Raise Price Targets for Quest Diagnostics and Arch Capital Group

Analysts have revised their outlook for Quest Diagnostics (DGX) and Arch Capital Group (ACGL), signaling positive momentum for both companies. For Quest Diagnostics, a group of six analysts established an average price target of $218.33, representing a potential upside of 9.17%. Similarly, twelve analysts adjusted their expectations for Arch Capital Group, raising the average price target to $105.0. Arch Capital's revision is supported by robust financial metrics, including a notable net profit margin of 26.92% and revenue growth of 10.95%. These updates reflect a broader bullish sentiment among market experts regarding the growth potential of these healthcare and insurance stocks. The revisions are driven by detailed quarterly assessments of market capitalization and operational performance.